Core Insights - A study by the American Cancer Society indicates that only about 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant opportunity to improve early detection and potentially prevent approximately 62,110 lung cancer deaths over five years [1] Company Developments - Tempus AI, Inc. has partnered with Median Technologies to integrate the eyonis LCS solution into the Tempus Pixel platform, enhancing lung cancer screening capabilities with AI-based software [2] - The company received FDA 510(k) clearance for its Tempus ECG-Low EF software, which identifies patients with low left ventricular ejection fraction [3] - Tempus strengthened its imaging capabilities through the acquisition of Arterys in 2022, integrating AI-driven imaging tools into its ecosystem [4] Peer Updates - GE HealthCare launched the Voluson Performance series and acquired icometrix to enhance its AI-powered brain imaging analysis capabilities [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' shares have declined by 14.3% over the past year, while the industry has seen a 33.6% decline, contrasting with a 17.7% increase in the S&P 500 [7] - The company currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 6.45X, above the industry average of 5.66X [11] Earnings Estimates - Tempus AI's loss per share estimate for 2025 has remained unchanged over the past 30 days, with current estimates at -$0.59 for the current year and -$0.21 for the next year [12][13]

Core Insights - Tempus AI, Inc. (TEM) has announced a collaboration with Median Technologies to integrate Median's eyonis LCS solution into the Tempus Pixel platform, enhancing AI capabilities in lung cancer screening and clinical decision-making [1][3][9] Company Developments - The eyonis LCS is an AI-enabled software-as-a-medical-device (SaMD) for lung cancer screening that has received FDA 510(k) clearance, facilitating its commercialization and clinical adoption [2] - The integration aims to support earlier and more accurate disease detection, assist radiologists with complex caseloads, and ultimately reduce preventable lung cancer deaths through improved access to advanced screening tools [3][5] - The collaboration is expected to strengthen Tempus AI's imaging-AI portfolio and expand the adoption of its Pixel platform, enhancing end-to-end lung cancer screening and workflow efficiency [5][9] - Tempus AI's current market capitalization stands at $9.24 billion [7] Market Context - The artificial intelligence in precision medicine market is projected to reach $4.28 billion by 2026, with a compound annual growth rate (CAGR) of 34.3% through 2035, driven by the increasing prevalence of cancer and demand for AI-powered diagnostic tools [12] - Research indicates that only 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant adoption gap that the eyonis LCS aims to address [10]

Core Insights - The FDA has approved Median Technologies' eyonis, an AI-based lung cancer detection tool, enhancing early cancer diagnosis capabilities [1][4]. Company Overview - Median Technologies is a French medtech company specializing in AI-driven software for medical diagnostics, particularly in lung cancer screening [2]. - The company has a market capitalization of €156 million [3]. Product Details - Eyonis lung cancer screening (LCS) is a computer-aided detection and diagnosis (CADe/CADx) software designed to analyze CT scan imaging data to assist radiologists in identifying and characterizing pulmonary nodules [2]. - The software demonstrated a sensitivity of 93.3%, specificity of 92.4%, and a 99.9% Negative Predictive Value (NPV) in performance testing [4]. Market Impact - Following the FDA approval announcement, Median's stock price surged by 19% to €5.10 ($6.06) at market open, and by 15:00 CET, it had increased by approximately 50% [3]. - The company plans to roll out eyonis LCS in the US through direct sales, strategic partnerships, and integration into existing clinical environments [5]. Financial Aspects - The software is expected to be reimbursed under the current US Medicare framework at a rate between $601 to $700, with plans for broader insurance coverage in the future [6]. - In January 2025, Median received a €37.5 million grant from the European Investment Bank and €10 million from IRIS Capital Investment to support its FDA filing and future European CE mark acquisition, expected in Q2 2026 [7]. Competitive Landscape - Median's FDA clearance follows a similar approval for RevealDX's lung nodule evaluation tool, indicating a growing market for AI-based diagnostic solutions in lung cancer [8].